What is Fathom Therapeutics?
Fathom Therapeutics is at the forefront of drug discovery, leveraging advanced physics-based simulations and artificial intelligence to engineer novel small molecules. The company's proprietary platform excels at modeling protein motion and interactions at an atomic level, enabling precise prediction of compound behavior within biological systems. This sophisticated approach facilitates more accurate therapeutic design and significantly reduces the likelihood of off-target effects. By integrating computational methods with laboratory-based validation, Fathom Therapeutics is accelerating the early stages of drug development, positioning itself as a key player in the pharmaceutical innovation landscape.
How much funding has Fathom Therapeutics raised?
Fathom Therapeutics has raised a total of $47M across 1 funding round:
Series A
$47M
Series A (2026): $47M with participation from Sutter Hill Ventures and Chemistry VC
Key Investors in Fathom Therapeutics
Sutter Hill Ventures
Sutter Hill Ventures is a prominent venture capital firm with a strong track record in financing technology-based startups and assisting entrepreneurs in building market-leading companies. Their expertise spans strategy, business development, and navigating the complexities of high-growth companies.
Chemistry VC
Chemistry VC is an early-stage venture capital firm focused on seed and Series A investments in standout software companies. Launched by experienced general partners, the firm emphasizes founder alignment and active support in sectors like fintech, infrastructure, and developer tools.
What's next for Fathom Therapeutics?
The substantial enterprise-level funding and recent strategic investment indicate Fathom Therapeutics is poised for significant expansion and technological advancement. This capital infusion is expected to fuel the acceleration of its drug discovery pipeline, enhance its AI and simulation capabilities, and potentially broaden its therapeutic focus areas. The company's trajectory suggests a move towards scaling its research and development efforts, solidifying strategic partnerships, and advancing its lead candidates through preclinical and clinical stages. Fathom Therapeutics' commitment to data-driven, computational drug design positions it to address complex diseases and capture a larger share of the pharmaceutical market.
See full Fathom Therapeutics company page
